BMO Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)

March 14, 2024 7:43 AM EDT Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $90.00 price target on Legend Biotech Corp. (NASDAQ: LEGN) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login